Cell study · normal human keratinocytes

LL-37 raised TLR9 and interferon output in human skin cells

Checked against the paper Cell studyPublished by PepVault

The takeaway

In human skin cells, LL-37 made them react more strongly to DNA with an interferon immune response, a pattern also seen in psoriasis skin.

Kind
Cell study
Studied in
Normal human keratinocytes
Published
2012
Journal
J Invest Dermatol

What they tested

The team asked whether LL-37 lets skin cells react to DNA through TLR9 (Toll-like receptor 9), and whether this ties in with psoriasis.

How the study was done

A lab study that compared skin from psoriasis lesions with normal skin, then exposed normal human keratinocytes (the main cells of the outer skin layer) grown in culture to LL-37, followed by TLR9 triggers such as CpG or genomic DNA.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking LL-37? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In psoriasis lesions, human keratinocytes showed more TLR9, in the same areas where LL-37 levels were higher. In cultured normal human keratinocytes, LL-37 raised TLR9 levels, and cells primed with LL-37 then given CpG or genomic DNA made much more type I interferon (immune signaling proteins). Psoriasis lesions likewise held more interferon-beta than normal skin without LL-37. This response needed TLR9 but did not depend on LL-37 binding to the DNA.

What it doesn’t show

Most of the work was in cultured skin cells, and the skin comparisons show patterns rather than cause. LL-37 was not tested as a treatment in people or animals.

The paper

Morizane et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol. 2012.

The compound

More studies on LL-37

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking LL-37? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo